[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100344058":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":13,"interventions":19,"overallOfficials":23,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":13,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":13,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":13,"maxAge":13,"enrollmentInfo":60,"targetDuration":13,"studyType":63,"phases":13,"briefSummary":64,"conditions":65,"keywords":13,"overallStatus":37,"whyStopped":13,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Patient overall survival will be measured and reported.","There will be one outcome measure: overall survival.","Through study completion, an average of 10 years",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","The overall goal of this proposal is to determine new molecular and cellular features that define tumor subtypes that are clinically actionable, may drive important changes in patient management, and\u002For elucidate novel chemotherapeutic options. Skull base tumors are currently diagnosed based on histopathologic criteria, on which post-operative management is based. However, the investigators hypothesize that each tumor type (eg. chordoma or chondrosarcoma) will have molecular and\u002For cellular subcategories that will redefine how to categorize and diagnose patients, predict clinical outcome, and optimally design a patient-specific management strategy. In addition, we aim to catalogue changes that occur after treatment after surgical resection, chemotherapy, and\u002For radiation by comparing primary and recurrent tumors.","Patients with a skull base tumor",[20],{"type":6,"name":21,"description":22,"armGroupLabels":13,"otherNames":13},"Observation","Understanding the biology of skull base tumors will teach the investigators about the genesis and\u002For mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.",[24],{"name":25,"affiliation":26,"role":27},"Paul Gardner, MD","Associate Professor","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":13,"email":33},"Benita Valappil, MPH","CONTACT","412-864-1744","valappilb2@upmc.edu",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of Pittsburgh Medical Center","RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-79.99589,40.44062,{"lat":47,"lon":46},[50],{"name":30,"role":31,"phone":32,"phoneExt":13,"email":33},{"type":27,"investigatorFullName":52,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Georgios Zenonos","100344058","molecular-and-cellular-characterization-of-skull-base-tumors-100344058",false,"NCT03759717","Molecular and Cellular Characterization of Skull Base Tumors","Inclusion Criteria:\n\n* Diagnosis of a skull base tumor\n\nExclusion Criteria:\n\n* Insufficient tumor sample at time of resection","ALL",{"count":61,"type":62},4000,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to analyze biological samples and genetic material for basic science research investigating the molecular and cellular characterization of skull base tumors.",[66,67],"Skull Base Neoplasm","Cellular Pathology","2026-09-21",{"date":70,"type":71},"2026-09-25","ACTUAL",{"date":73,"type":71},"2018-10-03",{"date":75,"type":62},"2028-10-03",{"name":5,"class":6},1]